Clinical Trial Detail

NCT ID NCT02471846
Title A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

bladder urothelial carcinoma

stomach cancer

Advanced Solid Tumor

head and neck cancer

triple-receptor negative breast cancer

renal cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

GDC-0919

Atezolizumab

Age Groups: adult

No variant requirements are available.